However, the recognition of a pityriasis rosea-like drug eruption in the context of TYK2 inhibition, coupled with previous reports associated with tyrosine kinase inhibitors and adalimumab,4 highlights the complex interplay between immune modulation and cutaneous manifestations. This evidence concerns the gene TYK2 and pityriasis rosea.